Want to see IN:SENORES full AI Analyst Report?
SENORES Stock Chart & Stats
₹716.90
--
Market closed
₹716.90
--
Day’s Range― - ―
52-Week Range₹661.65 - ₹1,599.55
Previous CloseN/A
VolumeN/A
Average Volume (3M)23.42K
Market Cap
₹64.74B
Enterprise Value₹37.04K
Total Cash (Recent Filing)₹3.60B
Total Debt (Recent Filing)₹2.41B
Price to Earnings (P/E)49.3
Beta0.95
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.35
Shares Outstanding46,053,590
10 Day Avg. Volume40,176
30 Day Avg. Volume23,424
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.63
Price to Sales (P/S)5.35
P/FCF Ratio-16.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)34.4
Revenue Forecast (FY)₹9.07B
Bulls Say, Bears Say
Bulls Say
FY2026 Revenue And Margin ExpansionThe sharp increase in revenue and strong FY2026 margins indicate materially greater operating scale and earnings capacity. If these economics persist, the company can reinvest in growth, strengthen its market position, and generate higher profits over the next several quarters.
Moderate Leverage And Rising EquityModerate leverage and a larger equity base provide some financial resilience as the business expands. The improvement in debt-to-equity suggests balance-sheet capacity has not deteriorated alongside growth, supporting investment and reducing dependence on aggressive borrowing.
Operating Cash Flow RecoveryThe return to positive operating cash flow is an encouraging change in underlying cash generation after the prior-year deficit. Although the amount remains modest relative to profits, continued improvement would support internally funded expansion and reduce reliance on external financing.
Bears Say
Persistently Negative Free Cash FlowSustained deeply negative free cash flow shows that reported profitability is not translating into cash available for debt reduction, dividends, or reinvestment. Continued cash consumption could require funding support and limits financial flexibility even while earnings remain strong.
Volatile Earnings PerformanceThe wide year-to-year change in profitability makes it harder to establish a dependable earnings base for the next two to six months. Cost volatility or one-off effects may have influenced results, increasing the risk that current margins are not fully sustainable.
Debt Burden And Balance-sheet UncertaintyAlthough leverage is described as moderate, 3.42B of total debt remains a meaningful obligation against a business with weak free cash flow. The reported asset inconsistency also lowers confidence in balance-sheet trend analysis and complicates assessment of financial resilience.
Senores Pharmaceuticals Ltd. News
SENORES FAQ
What was Senores Pharmaceuticals Ltd.’s price range in the past 12 months?
Senores Pharmaceuticals Ltd. lowest stock price was ₹661.65 and its highest was ₹1599.55 in the past 12 months.
What is Senores Pharmaceuticals Ltd.’s market cap?
Senores Pharmaceuticals Ltd.’s market cap is ₹64.74B.
When is Senores Pharmaceuticals Ltd.’s upcoming earnings report date?
Senores Pharmaceuticals Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 45 days.
How were Senores Pharmaceuticals Ltd.’s earnings last quarter?
Senores Pharmaceuticals Ltd. released its earnings results on Jul 27, 2026. The company reported ₹6.7 earnings per share for the quarter, beating the consensus estimate of ₹5.81 by ₹0.89.
Is Senores Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Senores Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Senores Pharmaceuticals Ltd. pay dividends?
Senores Pharmaceuticals Ltd. does not currently pay dividends.
What is Senores Pharmaceuticals Ltd.’s EPS estimate?
Senores Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senores Pharmaceuticals Ltd. have?
Senores Pharmaceuticals Ltd. has 46,053,590 shares outstanding.
What happened to Senores Pharmaceuticals Ltd.’s price movement after its last earnings report?
Senores Pharmaceuticals Ltd. reported an EPS of ₹6.7 in its last earnings report, beating expectations of ₹5.81. Following the earnings report the stock price went up 1.829%.
Which hedge fund is a major shareholder of Senores Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:SENORES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senores Pharmaceuticals Ltd.
Established in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Ltd. is actively involved in the development, manufacturing, and global commercialization of pharmaceutical and related products. Its extensive portfolio reaches markets across India, the United States, the United Kingdom, Canada, and other international territories. The company specializes in a diverse array of therapeutic solutions, encompassing analgesics/antipyretics, anesthetics, antibacterials, antivirals, antifungals, antioxidants, antineoplastics, blood-related therapies, cardiovascular and neurological medications, antacids, and vitamin and mineral supplements. Additionally, Senores offers a selection of generic drugs targeting pain, inflammation, fever, diabetes, malaria, and urinary tract conditions, as well as neutral supplements. Complementing its product offerings, the firm also provides management and consultancy services.
Technical Analysis
Abbott India Limited
―
Kopran Limited
―
Marksans Pharma Limited
―
Sanofi Consumer Healthcare India Limited
―
SMS Pharmaceuticals Limited
―